Myeloproliferative Neoplasms

home / expert-perspective-tumor-board / myeloproliferative-neoplasms

Experts in myeloproliferative neoplasms review 4 clinical cases and best practices for patients with, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and blast transformation.

Case 1: A 68-Year-Old Woman With Primary Myelofibrosis

EP. 1: Case 1: A 68-Year-Old Woman With Primary Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: Risk Stratification Models for Myelofibrosis

EP. 2: Case 1: Risk Stratification Models for Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: NCCN Guidelines for Treating Myelofibrosis

EP. 3: Case 1: NCCN Guidelines for Treating Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: Ruxolitinib Treatment for Myelofibrosis

EP. 4: Case 1: Ruxolitinib Treatment for Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: Fedratinib Treatment for Myelofibrosis

EP. 5: Case 1: Fedratinib Treatment for Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: The Diagnosis of Myelofibrosis

EP. 6: Case 1: The Diagnosis of Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 1: Transformation of Myelofibrosis to AML

EP. 7: Case 1: Transformation of Myelofibrosis to AML

Targeted Oncology
May 14th 2020

Watch

Case 1: Initiating Therapy for Myelofibrosis

EP. 8: Case 1: Initiating Therapy for Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 2: A 67-Year-Old Male With Polycythemia Vera

EP. 9: Case 2: A 67-Year-Old Male With Polycythemia Vera

Targeted Oncology
May 14th 2020

Watch

Case 2: NCCN Guidelines for Treating Polycythemia Vera

EP. 10: Case 2: NCCN Guidelines for Treating Polycythemia Vera

Targeted Oncology
May 14th 2020

Watch

Case 2: The RESPONSE Trial of Ruxolitinib for PV

EP. 11: Case 2: The RESPONSE Trial of Ruxolitinib for PV

Targeted Oncology
May 14th 2020

Watch

Case 2: The Diagnosis of Polycythemia Vera

EP. 12: Case 2: The Diagnosis of Polycythemia Vera

Targeted Oncology
May 14th 2020

Watch

Case 2: Ruxolitinib Treatment for Polycythemia Vera

EP. 13: Case 2: Ruxolitinib Treatment for Polycythemia Vera

Targeted Oncology
May 14th 2020

Watch

Case 3: A 39-Year-Old Female With Essential Thrombocythemia

EP. 14: Case 3: A 39-Year-Old Female With Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Case 3: Prediction of Thrombosis in Essential Thrombocythemia

EP. 15: Case 3: Prediction of Thrombosis in Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Case 3: Low- to Intermediate- Risk Essential Thrombocythemia

EP. 16: Case 3: Low- to Intermediate- Risk Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Case 3: Management of Essential Thrombocythemia

EP. 17: Case 3: Management of Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Case 3: Risk Assessment of Essential Thrombocythemia

EP. 18: Case 3: Risk Assessment of Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Transformation of Essential Thrombocythemia

EP. 19: Transformation of Essential Thrombocythemia

Targeted Oncology
May 14th 2020

Watch

Case 4: A 68-Year-Old Man With Primary Myelofibrosis

EP. 20: Case 4: A 68-Year-Old Man With Primary Myelofibrosis

Targeted Oncology
May 14th 2020

Watch

Case 4: Risk Factors and Genetic Abnormalities of MPN

EP. 21: Case 4: Risk Factors and Genetic Abnormalities of MPN

Targeted Oncology
May 14th 2020

Watch

Case 4: MPN Transition From Chronic- to Blast-Phase MPN

EP. 22: Case 4: MPN Transition From Chronic- to Blast-Phase MPN

Targeted Oncology
May 14th 2020

Watch

Case 4: Assessing Risk for Transformation to AML

EP. 23: Case 4: Assessing Risk for Transformation to AML

Targeted Oncology
May 14th 2020

Watch

Case 4: The Importance of Early Intervention in MPN

EP. 24: Case 4: The Importance of Early Intervention in MPN

Targeted Oncology
May 14th 2020

Watch